Compare Credo Technology Group Holding Ltd (CRDO) vs 10X Genomics Inc (TXG) Price & Performance

CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum showing bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth and 33.83% net income margins, though valuation metrics remain elevated with a P/E of 74.6. Recent earnings beats and analyst optimism highlight CRDO's position in AI infrastructure connectivity.

Outlook remains positive given triple-digit revenue growth and expanding AI data center demand, but premium valuation and insider selling present near-term risks. Wall Street consensus targets $267.33 with 87.5% buy ratings, though execution risks and customer concentration require monitoring amid rapid expansion.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.